Literature DB >> 18180268

Altered pharmacokinetics of cationic drugs caused by down-regulation of renal rat organic cation transporter 2 (Slc22a2) and rat multidrug and toxin extrusion 1 (Slc47a1) in ischemia/reperfusion-induced acute kidney injury.

Takanobu Matsuzaki1, Takafumi Morisaki, Wakako Sugimoto, Koji Yokoo, Daisuke Sato, Hiroshi Nonoguchi, Kimio Tomita, Tomohiro Terada, Ken-ichi Inui, Akinobu Hamada, Hideyuki Saito.   

Abstract

In the proximal tubules of rat (r) kidney, the polyspecific organic cation transporters (OCTs), rOCT1 and rOCT2, mediate the baso-lateral uptake of various organic cations, including many drugs, toxins, and endogenous compounds, and the apical type of H(+)/ organic cation antiporter, rat multidrug and toxin extrusion 1 (rMATE1), mediate the efflux of organic cations. Renal clearances of H(2) receptor antagonists, including famotidine, were reported to be decreased in patients with kidney disease. Therefore, acute kidney injury (AKI) could influence renal excretion and disposition of organic cations accompanied by the regulation of organic cation transporters. The aim of this study was to investigate the pharmacokinetic alteration of cationic drugs and the expression of tubular organic cation transporters, rOCT1, rOCT2, and rMATE1, in ischemia/reperfusion (I/R)-induced AKI rats. I/R-induced AKI increased the plasma concentration of i.v. administrated famotidine, a substrate for rOCT1 and rOCT2, or tetraethylammonium (TEA), a substrate for rOCT1, rOCT2, and rMATE1. The areas under the plasma concentration curves for famotidine and TEA were 2- and 6-fold higher in I/R rats than in sham-operated rats, respectively. The accumulation of TEA into renal slices was significantly decreased, suggesting that organic cation transport activity at the basolateral membranes was reduced in I/R rat kidney. The protein expressions of basolateral rOCT2 and luminal rMATE1 were down-regulated in I/R rat kidneys. These data suggest that the urinary secretion of cationic drugs via epithelial organic cation transporters is decreased in AKI.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180268     DOI: 10.1124/dmd.107.019869

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  19 in total

Review 1.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

2.  Ischemia/Reperfusion-inducible protein modulates the function of organic cation transporter 1 and multidrug and toxin extrusion 1.

Authors:  Qing Li; Hyekyung Yang; Xiujuan Peng; Dong Guo; Zhongqi Dong; James E Polli; Yan Shu
Journal:  Mol Pharm       Date:  2013-06-03       Impact factor: 4.939

3.  Characterization of the inhibitory effects of N-butylpyridinium chloride and structurally related ionic liquids on organic cation transporters 1/2 and human toxic extrusion transporters 1/2-k in vitro and in vivo.

Authors:  Yaofeng Cheng; Lucy J Martinez-Guerrero; Stephen H Wright; Robert K Kuester; Michelle J Hooth; I Glenn Sipes
Journal:  Drug Metab Dispos       Date:  2011-06-06       Impact factor: 3.922

Review 4.  Tubular Transport in Acute Kidney Injury: Relevance for Diagnosis, Prognosis and Intervention.

Authors:  Volker Vallon
Journal:  Nephron       Date:  2016-05-31       Impact factor: 2.847

5.  Characterization of the disposition and toxicokinetics of N-butylpyridinium chloride in male F-344 rats and female B6C3F1 mice and its transport by organic cation transporter 2.

Authors:  Y Cheng; S H Wright; M J Hooth; I G Sipes
Journal:  Drug Metab Dispos       Date:  2009-01-26       Impact factor: 3.922

6.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

7.  Cadmium exposure enhances organic cation transporter 2 trafficking to the kidney membrane and exacerbates cisplatin nephrotoxicity.

Authors:  Hong Yang; Jie Tang; Dong Guo; Qingqing Zhao; Jiagen Wen; Yanjuan Zhang; Obinna N Obianom; Shiwei Zhou; Wei Zhang; Yan Shu
Journal:  Kidney Int       Date:  2019-11-26       Impact factor: 10.612

8.  Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.

Authors:  Koji Yokoo; Risa Murakami; Takanobu Matsuzaki; Kanako Yoshitome; Akinobu Hamada; Hideyuki Saito
Journal:  Clin Exp Nephrol       Date:  2009-07-24       Impact factor: 2.801

9.  Urine NGAL and KIM-1 in children and adolescents with hyperuricemia.

Authors:  Justyna Tomczak; Anna Wasilewska; Robert Milewski
Journal:  Pediatr Nephrol       Date:  2013-05-15       Impact factor: 3.714

10.  Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats.

Authors:  Takafumi Morisaki; Takanobu Matsuzaki; Koji Yokoo; Masahiro Kusumoto; Kazufumi Iwata; Akinobu Hamada; Hideyuki Saito
Journal:  Pharm Res       Date:  2008-07-09       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.